Heart drug could shield brain after bleeding stroke

NCT ID NCT05664191

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether levosimendan, a heart medication that widens blood vessels, can reduce dangerous artery spasms and delayed brain injury after a type of bleeding stroke called aneurysmal subarachnoid hemorrhage. Thirty adults in intensive care will receive either levosimendan or a placebo on day 1 and day 8. The study tracks complications like death, vasospasm, and delayed brain ischemia over 14 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Levosimendan
What this could lead to: If it works, this could point toward a treatment to prevent brain damage after a bleeding stroke.
What could go wrong: This is a very small, early pilot study with only 30 patients, so results may not be conclusive. The drug may not reduce complications or could cause side effects like low blood pressure or fast heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEURYSMAL SUBARACHNOID HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage stroke disorder subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SUB-ARACHNOID HAEMORRHAGE

Contacts and locations

Locations

Hôpital Lariboisière, Service d'anesthésie Réanimation
RECRUITING

Paris, France, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.